# ZiO Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zio-health

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.elapta.com
- Total disclosed funding: $1M
- Latest round: Seed (Sep 30, 2019)
- Investors on record: 2

## About

ZiO Health Ltd. develops innovative therapeutic drug monitoring solutions through a proprietary biosensor technology, enhancing point-of-care testing to improve patient outcomes in healthcare settings.Founded in 2016 in London, UK, ZiO Health Ltd. specializes in drug monitoring technology. The company has raised GBP 1.4 million in funding as of March 2022, with a total valuation of GBP 15.18 million. Neel Patel, one of the founders, also serves as the CEO.ZiO Health specializes in therapeutic drug monitoring through its proprietary pocket-sized biosensor technology, enabling point-of-care laboratory testing aimed at improving patient outcomes. The core product offering includes an AI-driven handheld device that provides real-time quantitative results on drug concentrations in blood, particularly focusing on the monitoring of vancomycin levels. This technology allows for a proactive approach to dosing lifesaving medications, offering personalized dose information to maximize treatment efficacy and minimize toxicity. The devices are designed for use in clinical settings, catering to healthcare providers that require immediate data to make informed decisions about patient care. ZiO Health's products are primarily targeted towards healthcare markets in the United States and the United Kingdom, with a focus on hospitals and specialized clinics that administer critical medications.ZiO Health generates revenue through partnerships and direct sales of its biosensor technology and related services to healthcare providers and pharmaceutical companies. The company engages in business transactions that typically involve collaborations for research and development, as well as decentralized clinical trials, allowing partners to access its innovative biosensor platform. Pricing structures for its products are based on a per-test model, with the potential for long-term contracts or subscription-based services for continuous monitoring solutions. The primary offering, which focuses on vancomycin therapeutic drug monitoring, leverages a competitive pricing strategy that aims to reduce the costs associated with traditional laboratory testing methods. This approach not only enhances the efficiency of drug administration but also addresses the growing demand for precision medicine.In March 2022, ZiO Health Ltd. raised GBP 1.4 million of funding from undisclosed investors. The venture round values ZiO Health Ltd. at GBP 15.18 million post-money. The company plans to expand its product line with new advancements in biosensor technology aimed at enhancing therapeutic drug monitoring capabilities. Additionally, ZiO Health is targeting the U.S. and European markets for expansion by the end of 2023 to improve accessibility to its solutions. The recent funding will be utilized to support these product developments and market entry strategies.

## Funding rounds

- Seed, Sep 30, 2019, $0.5M — SOSV, HAX
- Seed, Sep 11, 2018, $0.3M — SOSV
- Seed, Aug 7, 2018, $0.2M — SOSV
- Seed, Feb 25, 2017 — SOSV, HAX

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- HAX — Seed